Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The regulatory capacity of B cells directs the aggressiveness of CLL.
Mohr A, Cumin M, Bagacean C, Pochard P, Le Dantec C, Hillion S, Renaudineau Y, Berthou C, Tempescul A, Saad H, Pers JO, Bordron A, Jamin C. Mohr A, et al. Among authors: renaudineau y. Oncoimmunology. 2018 Dec 12;8(3):1554968. doi: 10.1080/2162402X.2018.1554968. eCollection 2019. Oncoimmunology. 2018. PMID: 30723588 Free PMC article.
STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia.
Debant M, Burgos M, Hemon P, Buscaglia P, Fali T, Melayah S, Le Goux N, Vandier C, Potier-Cartereau M, Pers JO, Tempescul A, Berthou C, Bagacean C, Mignen O, Renaudineau Y. Debant M, et al. Among authors: renaudineau y. J Immunother Cancer. 2019 Apr 23;7(1):111. doi: 10.1186/s40425-019-0591-3. J Immunother Cancer. 2019. PMID: 31014395 Free PMC article.
Complement System: a Neglected Pathway in Immunotherapy.
Bordron A, Bagacean C, Tempescul A, Berthou C, Bettacchioli E, Hillion S, Renaudineau Y. Bordron A, et al. Among authors: renaudineau y. Clin Rev Allergy Immunol. 2020 Apr;58(2):155-171. doi: 10.1007/s12016-019-08741-0. Clin Rev Allergy Immunol. 2020. PMID: 31144209 Review.
Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy.
Bordron A, Bagacean C, Mohr A, Tempescul A, Bendaoud B, Deshayes S, Dalbies F, Buors C, Saad H, Berthou C, Pers JO, Renaudineau Y. Bordron A, et al. Among authors: renaudineau y. Oncotarget. 2018 Aug 3;9(60):31590-31605. doi: 10.18632/oncotarget.25657. eCollection 2018 Aug 3. Oncotarget. 2018. PMID: 30167081 Free PMC article.
Identification of altered cell signaling pathways using proteomic profiling in stable and progressive chronic lymphocytic leukemia.
Bagacean C, Iuga CA, Bordron A, Tempescul A, Pralea IE, Bernard D, Cornen M, Bergot T, Le Dantec C, Brooks W, Saad H, Ianotto JC, Pers JO, Zdrenghea M, Berthou C, Renaudineau Y. Bagacean C, et al. Among authors: renaudineau y. J Leukoc Biol. 2022 Feb;111(2):313-325. doi: 10.1002/JLB.4HI0620-392R. Epub 2021 Jul 20. J Leukoc Biol. 2022. PMID: 34288092
Rapid and complete response to idelalisib in a case of Richter syndrome.
Bagacean C, Zdrenghea M, Saad H, Berthou C, Renaudineau Y, Tempescul A. Bagacean C, et al. Among authors: renaudineau y. Onco Targets Ther. 2019 Feb 13;12:1181-1184. doi: 10.2147/OTT.S187459. eCollection 2019. Onco Targets Ther. 2019. PMID: 30863085 Free PMC article.
Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion.
Bagacean C, Le Dantec C, Berthou C, Tempescul A, Saad H, Bordron A, Zdrenghea M, Cristea V, Douet-Guilbert N, Renaudineau Y. Bagacean C, et al. Among authors: renaudineau y. Clin Epigenetics. 2017 Nov 28;9:122. doi: 10.1186/s13148-017-0422-7. eCollection 2017. Clin Epigenetics. 2017. PMID: 29209431 Free PMC article.
189 results